Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904216 | 0.91 | MAPT (0.59) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| SCHEMBL2089573 | 0.80 | CYP1A2 (0.50) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| SCHEMBL2089572 | 0.80 | CYP1A2 (0.50) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| SCHEMBL754265 | 0.80 | CYP1A2 (0.50) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| SCHEMBL18901727 | 0.77 | CHRM3 (0.47) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3755368 | 0.77 | TAAR1 (0.44) | MAPTKMT2AKCNN4CYP1A2NR1H2 | |
| SCHEMBL13389065 | 0.74 | CHRM3 (0.48) | MAPTKMT2ACHRM3KCNN4CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28429332 | 0.74 | CYP1A2 (0.50) | MAPTKMT2AKCNN4CYP1A2PTPN1 | |
| SCHEMBL1822224 | 0.72 | MAPT (0.63) | MAPTKMT2AKCNN4CYP1A2PTPN1 | |
| SCHEMBL17827512 | 0.72 | CES1 (0.50) | MAPTKMT2ACHRM3KCNN4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | MAPT 68/4885KMT2A 943/4885CHRM3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.